View of Treatment outcomes and factors associated with treatment failure among patients with mild-to-moderate COVID-19 receiving five-days of oral molnupiravir vs. three-days of intravenous remdesivir in a real-world practice

Return to Article Details Treatment outcomes and factors associated with treatment failure among patients with mild-to-moderate COVID-19 receiving five-days of oral molnupiravir vs. three-days of intravenous remdesivir in a real-world practice Download Download PDF